查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083733

基因組編輯市場：按技術、治療領域、遞送方式、應用和最終用戶分類－2026-2032年全球市場預測

Genome Editing Market by Technology, Therapeutic Area, Delivery Method, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，基因組編輯市場將成長至 217.1 億美元，複合年成長率為 10.96%。

主要市場統計數據
基準年 2025 104.8億美元
預計年份：2026年 115.9億美元
預測年份：2032年 217.1億美元
複合年成長率 (%) 10.96%

基因組編輯已從一項突破性的研究進展轉變為一項對治療藥物研發具有臨床和商業性應用價值的技術。 CRISPR-Cas系統、鋅指核酸酶、TALENs、鹼基編輯、先導編輯和RNA誘導的表觀遺傳學編輯正在重塑製藥和生物技術研發人員應對單基因疾病、腫瘤、免疫學、感染疾病和罕見疾病的方式。

2023年和2024年，基於CRISPR技術的exa-cel獲得了多項里程碑式的監管批准，包括美國FDA、英國MHRA、歐盟委員會和其他國家監管機構的批准，用於治療鐮狀細胞病和輸血依賴型BETA-地中海貧血，這為該領域的臨床療效提供了顯著支持。對於療法研發者而言，基因組編輯技術的現況取決於臨床差異化、遞送效率、脫靶風險控制、可擴展生產、倫理管治以及持續證據的產生。

治療前景的變革性變化

基因組編輯技術正從第一代基於核酸酶的切割方法轉向更精確的技術。鹼基編輯技術能夠在不造成雙鏈斷裂的情況下對單一鹼基進行DNA修飾，而先導編輯技術則透過支援標靶插入、缺失和替換，擴展了可程式設計修飾的可能性。這些方法正在加速血液學、肝病、眼科學、腫瘤學、免疫介導性疾病和遺傳代謝紊亂等領域的基因組編輯流程的擴展。

人工智慧的累積影響

人工智慧正在加速整個基因組編輯價值鏈的發展。機器學習模型正被用於設計引導RNA、預測標靶效率、評估脫靶活性、最佳化編輯器結構、識別致病突變以及確定疾病相關標靶的優先順序。蛋白質結構預測領域的最新進展，包括基於AlphaFold的生物學方法，也在加速酵素工程、功能註釋和標靶檢驗。

基因組編輯的關鍵區域見解

北美憑藉著雄厚的生物醫學研究經費、一流的學術醫療中心、美國食品藥物管理局（FDA）在基因和細胞療法審查方面的經驗、成熟的臨床試驗基礎設施以及符合GMP規範的生物製造能力，在治療性基因組編輯領域保持領先地位。歐洲除了擁有強大的生物醫學研究實力外，還受益於歐洲藥品管理局（EMA）的監管、國家醫療技術評估要求、一般資料保護規則（GDPR）下的資料管治以及對生殖細胞編輯的嚴格倫理要求。以中國、日本、韓國、澳洲和印度主導的亞太地區正在快速發展，這得益於其強大的臨床研究能力、不斷擴展的精準醫療計畫以及各國政府對生物技術自主化的日益重視。

關於策略聯盟的關鍵集團洞察

七國集團（G7）透過公共研究經費、監管先例、智慧財產權創造、臨床試驗密度和先進生物製造等方式，為治療性基因組編輯生態系統提供了強而有力的支持。歐盟在協調藥品法規、跨境研究管治、資料保護、倫理監督以及就農業和醫療領域新興基因組技術開展持續政策討論方面發揮著核心作用。北約成員國日益從「兩用」和「生物安全」的角度看待合成生物學和基因組編輯，並支持加強對敏感研究、生物數據和相關技術的保護。

主要國家在引入基因組編輯方面的趨勢

美國在臨床應用、FDA先例、創業投資支持的生物技術、大學衍生公司以及先進細胞和基因療法的生產製造方面處於主導地位。加拿大在基因組學、幹細胞研究、人口健康數據和臨床網路方面表現出色，而墨西哥則擁有不斷擴展的臨床試驗能力、跨境醫療保健的重要性以及區域製造潛力。巴西在拉丁美洲的生物技術監管、研究規模、農業生物技術經驗以及大規模的患者群體方面都佔據核心地位。

為行業領導者提供的實用建議

產業領導者應優先考慮基因組編輯相比現有療法具有明顯臨床優勢的適應症，例如一次性功能性治療、持續緩解、減輕治療負擔或差異化安全性。遞送策略不應僅被視為輔助技術，而應被視為核心平台資產，因為組織標靶化、酬載限制、體內分佈和免疫反應管理往往決定臨床可行性。

調查方法

本執行摘要資訊來源檢驗公開來源的二手研究，包括監管公告、同行評審文獻、臨床實驗室註冊資訊、政府政策文件、公共衛生指南以及關於基因組編輯、基因治療和先進療法的技術文獻。本文的研究結果反映了已記錄的重要進展，例如 CRISPR 療法的批准、世界衛生組織的管治建議、國家法規結構以及關於編輯效率、遞送系統和安全性評估的同行評審證據。

結論

基因組編輯正進入一個更嚴格的階段，科學創新必須轉化為安全、永續、可生產、符合倫理規範且健保覆蓋的產品。首批 CRISPR 療法的核准證明，可程式設計編輯技術已觸手可及，但其更廣泛的應用將取決於遞送技術的創新、監管機構的信譽、生產規模、長期安全性監測以及臨床證據的品質。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 基因組編輯市場：依技術分類

  • 基礎編輯
    • 腺嘌呤鹼基編輯器
    • 胞嘧啶鹼基編輯器
  • CRISPR
    • Cas12
    • Cas13
    • Cas9
  • MegaTAL
  • Prime Edit
  • TALEN
  • ZFN

第8章：基因組編輯市場：依治療領域分類

  • 循環系統
  • 遺傳性疾病
  • 感染疾病
  • 神經病學
  • 腫瘤學

第9章：基因組編輯市場：依交付方式分類

  • 非病毒
    • 電穿孔
    • 脂質奈米顆粒
  • 物理方法
    • 基因槍
    • 顯微注射
  • 病毒載體

第10章 基因組編輯市場：依應用領域分類

  • 農業
    • 作物改良
    • 畜牧業改良
  • 工業生物技術
    • 生質燃料
    • 生物製造
  • 研究
    • 基礎研究
    • 藥物發現
  • 治療
    • 細胞療法
    • 基因治療

第11章 基因組編輯市場：依最終使用者分類

  • 學術機構
  • 受託研究機構
  • 製藥和生物技術公司

第12章 基因組編輯市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 基因組編輯市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 基因組編輯市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Agilent Technologies, Inc.
  • AMS BIoTechnology Ltd.
  • Arbor BIoTechnologies Inc
  • Beam Therapeutics Inc.
  • Caribou Biosciences Inc.
  • Cellectis SA
  • Century Therapeutics Inc
  • Creative Biogene
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine Inc
  • GenScript
  • Gilead Sciences Inc
  • Horizon Discovery Group PLC
  • Intellia Therapeutics Inc
  • Lonza Group Ltd.
  • Mammoth Biosciences
  • Merck KGaA
  • Metagenomi
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Poseida Therapeutics Inc
  • Precision BioSciences Inc
  • Prime Medicine Inc
  • Regeneron Pharmaceuticals Inc
  • Sangamo Therapeutics Inc
  • Scribe Therapeutics
  • Synthego Corporation
  • Takara Bio Inc.
  • Tessera Therapeutics Inc
  • Thermo Fisher Scientific Inc
  • Vertex Pharmaceuticals Incorporated
  • Verve Therapeutics Inc
Product Code: MRR-431C35F6C15D

The Genome Editing Market is projected to grow by USD 21.71 billion at a CAGR of 10.96% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.48 billion
Estimated Year [2026] USD 11.59 billion
Forecast Year [2032] USD 21.71 billion
CAGR (%) 10.96%

Genome editing has moved from a research breakthrough to a clinical and commercial capability for therapeutic innovators. CRISPR-Cas systems, zinc finger nucleases, TALENs, base editing, prime editing, and RNA-guided epigenetic editing are reshaping how pharmaceutical and biotechnology developers address monogenic disease, oncology, immunology, infectious disease, ophthalmology, and rare disorders.

The sector gained major clinical validation when CRISPR-based exa-cel received landmark regulatory authorizations for sickle cell disease and transfusion-dependent beta thalassemia in 2023 and 2024, including approvals by the U.S. FDA, the U.K. MHRA, the European Commission, and other national authorities. For therapy developers, the genome editing landscape is now defined by clinical differentiation, delivery efficiency, off-target risk management, scalable manufacturing, ethical governance, and durable evidence generation.

Transformative Shifts in the Therapeutic Landscape

The genome editing landscape is shifting from first-generation nuclease cutting toward higher-precision modalities. Base editing enables single-letter DNA changes without double-strand breaks, while prime editing broadens programmable correction potential by supporting targeted insertions, deletions, and substitutions. These approaches are accelerating pipeline expansion across hematology, liver disease, ophthalmology, oncology, immune-mediated disorders, and inherited metabolic conditions.

Commercial strategy is also changing. Ex vivo editing benefits from controlled manufacturing and established cell therapy infrastructure, while in vivo genome editing depends on safer delivery through lipid nanoparticles, viral vectors, and tissue-targeted systems. Regulatory expectations increasingly emphasize long-term follow-up, validated off-target assays, transparent patient monitoring, product comparability, and risk-based assessment of permanent genomic changes.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding progress across the genome editing value chain. Machine learning models are used to design guide RNAs, predict on-target efficiency, assess off-target activity, optimize editor architecture, identify pathogenic variants, and prioritize targets with stronger disease relevance. Public advances in protein structure prediction, including AlphaFold-enabled biology, have also accelerated enzyme engineering, functional annotation, and target validation.

For therapeutic developers, AI reduces experimental search space but does not replace wet-lab validation. The strongest competitive advantage comes from combining high-quality genomic datasets, single-cell and multi-omics data, functional screens, clinically annotated cohorts, and rigorous bioinformatics with compliant model governance that supports reproducible, regulator-ready evidence.

Key Regional Insights for Genome Editing

North America remains a therapeutic genome editing leader due to deep biomedical funding, major academic medical centers, FDA experience in gene and cell therapy review, mature clinical trial infrastructure, and established GMP biomanufacturing capacity. Europe combines strong biomedical research with EMA oversight, national health technology assessment requirements, General Data Protection Regulation-driven data governance, and strict ethical expectations around germline editing. Asia-Pacific is advancing rapidly, led by China, Japan, South Korea, Australia, and India, with strong clinical research capacity, expanding precision medicine programs, and growing policy attention to biotechnology self-sufficiency.

Latin America is building relevance through Brazil and Mexico, especially in clinical research participation, public health genomics, and agricultural biotechnology spillovers. The Middle East is investing in genomic medicine through national programs in Saudi Arabia, the UAE, Qatar, and other Gulf states, strengthening sequencing infrastructure and specialty care pathways. Africa's opportunity is tied to inherited blood disorders, infectious disease, crop resilience, and capacity-building initiatives, although laboratory infrastructure, financing, and regulatory harmonization remain uneven across the region.

Key Group Insights Across Strategic Alliances

The G7 anchors much of the therapeutic genome editing ecosystem through public research funding, regulatory precedent, intellectual property generation, clinical trial density, and advanced biomanufacturing. The European Union plays a central role in harmonized medicines regulation, cross-border research governance, data protection, ethics oversight, and ongoing policy debates over new genomic techniques in agriculture and health. NATO economies increasingly view synthetic biology and genome editing through a dual-use and biosecurity lens, supporting stronger safeguards for sensitive research, biological data, and enabling technologies.

BRICS countries are important for scale, clinical recruitment, agricultural application, public health genomics, and cost-efficient R&D, with China, India, and Brazil particularly influential. ASEAN is emerging through biomedical research hubs in Singapore, Thailand, and Malaysia, while food security, aquaculture, and infectious disease priorities support broader regional relevance. The GCC is using national genomics initiatives, hospital modernization, and precision medicine programs to create demand for advanced diagnostics, cell therapies, rare disease management, and future genome editing partnerships.

Key Country Insights for Genome Editing Adoption

The United States leads in clinical translation, FDA precedents, venture-backed biotechnology, academic spinouts, and advanced cell and gene therapy manufacturing. Canada contributes strength in genomics, stem cell research, population health data, and clinical networks, while Mexico offers expanding trial capacity, cross-border healthcare relevance, and regional manufacturing potential. Brazil is the Latin American anchor for biotechnology oversight, research scale, agricultural biotechnology experience, and large patient population access.

In Europe, the United Kingdom remains influential through MHRA innovation pathways, national genomics infrastructure, and translational research networks, while Germany and France bring pharmaceutical depth, public research institutes, advanced engineering, and biomanufacturing capability. Italy and Spain support clinical research, rare disease networks, and hospital-based translational medicine, while Russia maintains scientific capacity in molecular biology and biotechnology despite geopolitical constraints. In Asia-Pacific, China is a major clinical research and manufacturing force, India is expanding genomics, bioeconomy policy, and gene editing applications for agriculture and health, Japan offers regenerative medicine expertise and a structured regulatory pathway for advanced therapies, Australia provides strong translational research and clinical trial quality, and South Korea brings advanced biopharma, digital health integration, and CDMO capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indications where genome editing offers clear clinical superiority over existing therapy, such as one-time functional cures, durable remission, reduced treatment burden, or differentiated safety. Delivery strategy should be treated as a core platform asset, not a supporting technology, because tissue targeting, payload constraints, biodistribution, and immune response management often determine clinical feasibility.

Developers should invest early in off-target detection, long-term follow-up systems, scalable GMP manufacturing, payer evidence packages, patient access planning, and ethical review processes. Strategic partnerships with AI platform specialists, academic genome centers, CDMOs, clinical trial networks, and patient advocacy organizations can shorten development timelines while improving credibility with regulators, clinicians, and payers.

Research Methodology

This executive summary is grounded in secondary research from verified public sources, including regulatory agency releases, peer-reviewed literature, clinical trial registries, government policy documents, public health guidance, and technical publications on genome editing, gene therapy, and advanced therapeutics. Insights reflect documented milestones such as CRISPR therapeutic approvals, WHO governance recommendations, national regulatory frameworks, and peer-reviewed evidence on editing efficiency, delivery systems, and safety evaluation.

The analysis synthesizes technology adoption, regional readiness, clinical translation, manufacturing feasibility, policy signals, and ethical governance. No unsupported revenue estimates are used; emphasis is placed on validated developments, observable investment and research patterns, approved products, clinical-stage activity, public regulatory positions, and reproducible scientific evidence.

Conclusion

Genome editing is entering a more disciplined phase in which scientific novelty must translate into safe, durable, manufacturable, ethically governed, and reimbursable products. The first CRISPR therapy approvals proved that programmable editing can reach patients, but broader adoption will depend on delivery innovation, regulatory trust, manufacturing scale, long-term safety monitoring, and clinical evidence quality.

Therapeutic leaders that integrate AI-enabled design, robust validation, ethical governance, and global access strategy will be better positioned to build sustainable advantage. The next phase of genome editing will reward organizations that move beyond platform promise and demonstrate measurable patient outcomes across well-defined clinical settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Genome Editing Market, by Technology

  • 7.1. Base Editing
    • 7.1.1. Adenine Base Editor
    • 7.1.2. Cytosine Base Editor
  • 7.2. CRISPR
    • 7.2.1. Cas12
    • 7.2.2. Cas13
    • 7.2.3. Cas9
  • 7.3. MegaTAL
  • 7.4. Prime Editing
  • 7.5. TALEN
  • 7.6. ZFN

8. Genome Editing Market, by Therapeutic Area

  • 8.1. Cardiology
  • 8.2. Genetic Disorders
  • 8.3. Infectious Diseases
  • 8.4. Neurology
  • 8.5. Oncology

9. Genome Editing Market, by Delivery Method

  • 9.1. Nonviral
    • 9.1.1. Electroporation
    • 9.1.2. Lipid Nanoparticles
  • 9.2. Physical Methods
    • 9.2.1. Gene Gun
    • 9.2.2. Microinjection
  • 9.3. Viral Vector

10. Genome Editing Market, by Application

  • 10.1. Agricultural
    • 10.1.1. Crop Improvement
    • 10.1.2. Livestock Improvement
  • 10.2. Industrial Biotechnology
    • 10.2.1. Biofuels
    • 10.2.2. Biomanufacturing
  • 10.3. Research
    • 10.3.1. Basic Research
    • 10.3.2. Drug Discovery
  • 10.4. Therapeutics
    • 10.4.1. Cell Therapy
    • 10.4.2. Gene Therapy

11. Genome Editing Market, by End User

  • 11.1. Academic Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Biotech

12. Genome Editing Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Genome Editing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Genome Editing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Agilent Technologies, Inc.
  • 16.2. AMS Biotechnology Ltd.
  • 16.3. Arbor Biotechnologies Inc
  • 16.4. Beam Therapeutics Inc.
  • 16.5. Caribou Biosciences Inc.
  • 16.6. Cellectis SA
  • 16.7. Century Therapeutics Inc
  • 16.8. Creative Biogene
  • 16.9. CRISPR Therapeutics AG
  • 16.10. Danaher Corporation
  • 16.11. Editas Medicine Inc
  • 16.12. GenScript
  • 16.13. Gilead Sciences Inc
  • 16.14. Horizon Discovery Group PLC
  • 16.15. Intellia Therapeutics Inc
  • 16.16. Lonza Group Ltd.
  • 16.17. Mammoth Biosciences
  • 16.18. Merck KGaA
  • 16.19. Metagenomi
  • 16.20. New England Biolabs, Inc.
  • 16.21. OriGene Technologies, Inc.
  • 16.22. Poseida Therapeutics Inc
  • 16.23. Precision BioSciences Inc
  • 16.24. Prime Medicine Inc
  • 16.25. Regeneron Pharmaceuticals Inc
  • 16.26. Sangamo Therapeutics Inc
  • 16.27. Scribe Therapeutics
  • 16.28. Synthego Corporation
  • 16.29. Takara Bio Inc.
  • 16.30. Tessera Therapeutics Inc
  • 16.31. Thermo Fisher Scientific Inc
  • 16.32. Vertex Pharmaceuticals Incorporated
  • 16.33. Verve Therapeutics Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOME EDITING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL GENOME EDITING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL GENOME EDITING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL GENOME EDITING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOME EDITING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL GENOME EDITING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL GENOME EDITING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL GENOME EDITING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL GENOME EDITING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL GENOME EDITING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BASE EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BASE EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BASE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADENINE BASE EDITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADENINE BASE EDITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADENINE BASE EDITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CYTOSINE BASE EDITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CYTOSINE BASE EDITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CYTOSINE BASE EDITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CRISPR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRISPR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CRISPR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CAS12 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CAS12 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CAS12 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CAS13 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAS13 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAS13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAS9 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CAS9 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CAS9 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MEGATAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MEGATAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MEGATAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRIME EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRIME EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRIME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TALEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TALEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TALEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ZFN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ZFN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ZFN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENETIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENETIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NONVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NONVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NONVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ELECTROPORATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ELECTROPORATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ELECTROPORATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHYSICAL METHODS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHYSICAL METHODS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHYSICAL METHODS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE GUN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE GUN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE GUN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MICROINJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MICROINJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MICROINJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AGRICULTURAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AGRICULTURAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AGRICULTURAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CROP IMPROVEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CROP IMPROVEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CROP IMPROVEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVESTOCK IMPROVEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LIVESTOCK IMPROVEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVESTOCK IMPROVEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INDUSTRIAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INDUSTRIAL BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INDUSTRIAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOFUELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOFUELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOFUELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOMANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BASIC RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BASIC RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BASIC RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PHARMACEUTICAL BIOTECH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PHARMACEUTICAL BIOTECH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PHARMACEUTICAL BIOTECH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL GENOME EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GCC GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. GCC GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 224. GCC GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 225. GCC GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 226. GCC GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. GCC GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 228. GCC GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. GCC GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 231. GCC GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 233. GCC GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. G7 GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. G7 GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. G7 GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 266. G7 GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 267. G7 GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 268. G7 GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 269. G7 GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 270. G7 GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. G7 GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 273. G7 GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 275. G7 GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 276. G7 GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. NATO GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. NATO GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 280. NATO GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 281. NATO GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 282. NATO GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 283. NATO GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 284. NATO GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 285. NATO GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. NATO GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 287. NATO GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. NATO GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 289. NATO GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. CANADA GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. CANADA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. CANADA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. MEXICO GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. MEXICO GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. MEXICO GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 332. MEXICO GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. BRAZIL GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. BRAZIL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. BRAZIL GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 337. BRAZIL GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 338. BRAZIL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 339. BRAZIL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 340. BRAZIL GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 341. BRAZIL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 342. BRAZIL GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 343. BRAZIL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 344. BRAZIL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 345. BRAZIL GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 346. BRAZIL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 347. BRAZIL GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED KINGDOM GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 350. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 352. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 355. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 356. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 358. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 359. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 360. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 361. UNITED KINGDOM GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 362. GERMANY GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 363. GERMANY GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 364. GERMANY GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 365. GERMANY GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 366. GERMANY GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 367. GERMANY GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 368. GERMANY GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 369. GERMANY GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 370. GERMANY GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 371. GERMANY GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 372. GERMANY GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 373. GERMANY GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 374. GERMANY GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 375. GERMANY GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 376. FRANCE GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 377. FRANCE GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 378. FRANCE GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 379. FRANCE GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 380. FRANCE GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 381. FRANCE GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 382. FRANCE GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 383. FRANCE GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 384. FRANCE GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 385. FRANCE GENOME EDITING MARKET SIZE, BY AGR